Cosalane compounds and methods for their use

Details Cosalane compounds and methods for their use Cosalane compounds and methods for their use

2006-10-17

2006-10-17

Qazi, Sabiha N. (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S171000, C514S182000, C552S506000, C552S540000, C552S552000, C552S565000

Reexamination Certificate

active

07122533

ABSTRACT:
The present invention relates to methods, compounds and compositions for inhibiting effective binding of a chemokine to its cellular receptor. In one form of the invention, a method includes contacting a cellular population with an effective amount of cosalane or an analog thereof. The invention further relates to methods, compounds and compositions for treating inflammatory diseases. In one form, a method includes administering to a patient a therapeutically effective amount of cosalane or an analog thereof.

REFERENCES:
patent: 5237110 (1993-08-01), DeLuca et al.
patent: 5246925 (1993-09-01), DeLuca et al.
patent: 5428029 (1995-06-01), Doran et al.
patent: 5439899 (1995-08-01), Cushman et al.
patent: 5484782 (1996-01-01), DeLuca et al.
patent: 5536713 (1996-07-01), Deluca et al.
patent: 5587497 (1996-12-01), DeLuca et al.
patent: 6562805 (2003-05-01), Cushman et al.
patent: 2005/0063992 (2005-03-01), Keys
patent: 2005/0065087 (2005-03-01), Campagnari
patent: 2005/0065088 (2005-03-01), Thompson
patent: 2005/0065117 (2005-03-01), Lee
patent: 2005/0065126 (2005-03-01), Lee
patent: 2005/0065130 (2005-03-01), Thompson
patent: 2005/0065133 (2005-03-01), Lee et al.
patent: 2005/0065180 (2005-03-01), Lee
patent: 2005/0070512 (2005-03-01), Lee
patent: 2005/0119242 (2005-06-01), DeLuca et al.
patent: 2005/0143358 (2005-06-01), DeLuca et al.
Alkhatib et al., “CC CKR5: A Rantes, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1,”Science272:1955-58 (1996).
Choe et al., “The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates,”Cell85:1135-48 (1996).
Dean et al., “Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of theCKR5structural gene,”Science273:1856-62 (1996).
Deng et al., “Identification of a major co-receptor for primary isolates of HIV-1,”Nature381:661-66 (1996).
Dragic et al., “HIV-1 entry into CD4+cells is mediated by the chemokine receptor CC-CKR-5,”Nature381:667-73 (1996).
Gangur et al., “Are chemokines essential or secondary participants in allergic responses?”Ann. Allergy Asthma, Immunol. 84:569-81 (2000).
Liang et al., “Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1,”J. Biol. Chem. 275:19000-08 (2000).
Moore et al., “CXC chemokines mechanism of action in regulating tumor angiogenesis,”Angiogenesis2:123-34 (1998).
Murata et al., “Novel palladium(0)-catalyzed coupling reaction of dialkoxyborane with aryl halides: Convenient synthetic route to arylboronates,”J. Org. Chem. 62:6458-59 (1997).
Ng et al., “Discovery of novel non-peptide CCR1 receptor antagonists,”J. Med. Chem. 42:4680-94 (1999).
Robinson et al., “Mechanisms of allergic asthma: A Th2 disease,”Lung Biol. Health Dis. 136:9-41 (1999).
Wang et al., “Human recombinant macrophage inflammatory protein-1α and -β and monocyte chemotactic and activating factor utilize common and unique receptors on human monocytes, ”J. Immunol. 150:3022-29 (1993).
Zlotnik et al., “Recent advances in chemokines and chemokine receptors,”Crit. Rev. Immunol. 19:1-47 (1999).
Casimiro-Garcia et al., “Synthesis and anti-HIV activity of cosalane analogues incorporating nitrogen in the linker chain,”Bioorg. Med. Chem. Lett. 8:191-200 (2000).
Cushman et al., “Extension of the polyanionic cosalane pharmacophore as a strategy for increasing anti-HIV potency,”J. Med. Chem. 42:1767-77 (1999).
Cushman et al., “Synthesis of a cosalane analog with an extended polyanionic pharmacophore conferring enhanced potency as an anti-HIV agent,”Bioorg. Med. Chem. Lett. 8:833-36 (1998).
Cushman et al., “Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase,”J. Med. Chem. 38:443-52 (1995).
Cushman et al., “Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction,”J. Med. Chem. 37:3040-50 (1994).
Golebiewski et al., “Exploration of the effects of linker chain modifications on anti-HIV activities in a series of cosalane analogues,”Bioorg. Med. Chem. Lett. 4(10):1637-48 (1996).
Golebiewski et al., “Design and synthesis of cosalane, a novel anti-HIV agent,”Bioorg. Med. Chem. Lett.3(8):1739-42 (1993).
Howard et al., “Inhibition of RANTES/CCR-1-mediated chemotaxis by cosalane and related compounds,”Bioorg. Med. Chem. Lett. 11:59-62 (2001).
Keyes et al., Correlation of anti-HIV potency with lipophilicity in an series of cosalane analogs having normal alkenyl and phosphodiester chains as cholestane replacements,J. med. Chem. 39:508-14 (1996).
Keyes et al., “Studies directed toward a more potent cosalene pharmacophore: Synthesis of a substituted tetraphenylethylene which inhibits the cytophatic effect of HIV-1,”Med. Chem. Res. 39:372-76 (1996).
Paul et al., “Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates,”Bioorg. Med. Chem. Lett. 10:2149-52 (2000).
Ruell et al., “Synthesis and anti-HIV activity of cosalane analogues with substituted benzoic acid rings attached to the pharmacophore through methylene and amide linkers,”J. Org. Chem. 64:5858-66 (1999).
Santhosh et al., “Anti-HIV activity of a series of cosalane amino acids conjugates,”Bioorg. Med. Chem. Lett. 10:2505-08 (2000).
Kuchimanchi et al., “Intestinal absorption and biodistribution of cosalane and its amino acid conjugates: Novelanti-HIV agents,”International. J. Pharmaceutics231:197-211 (2002).

Affiliated with

Also associated with

Rating

Cosalane compounds and methods for their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cosalane compounds and methods for their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cosalane compounds and methods for their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3616630